Fig. 1
From: Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Rate of decline in forced vital capacity (FVC) (mL/year) with nintedanib and placebo (a) and relative treatment effect of nintedanib (b) over 52 weeks in subgroups taking or not taking glucocorticoids at baseline. Glucocorticoids were taken at a dose of > 20 mg/day prednisone or equivalent by 8 subjects. HRCT high-resolution computed tomography, UIP usual interstitial pneumonia